Electrostatic Applicator for Uniform Wound Treatment Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for applying disinfectants and treatments to patients, particularly for skin wounds, are inefficient and prone to infection, with traditional spraying methods being ineffective and stem cell treatments requiring lengthy and costly processes.

Innovation Solution

An electrospun applicator that uniformly applies a treatment solution, including stem cells and disinfectants, by using a rotatable needle with a distal nozzle tip to deliver electrically spun droplets directly to the treatment site, creating a fine mist or fibrous mat.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If traditional spraying methods are used to apply disinfectants, then the application process is simple, but the uniformity and effectiveness of treatment is poor

Engineering Contradiction:
Improveuniformity of treatment applicationVSAvoidcomplexity of applicator device
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent replaces traditional mechanical spraying systems with an electrostatic application system. The applicator uses electrostatic charges to attract and deposit treatment solution uniformly across the treatment site, eliminating the uneven coverage problems of conventional spray methods while maintaining operational simplicity through automated charge distribution.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The invention changes the physical parameters of treatment solution delivery by controlling electrostatic charge density, voltage levels, and droplet size distribution. These parameter adjustments enable precise control over treatment uniformity and penetration depth, significantly improving application quality compared to traditional mechanical spraying.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If stem cell treatments are grown and maintained in culture, then the treatment effectiveness is improved, but the time and cost required increases significantly

Engineering Contradiction:
Improveeffectiveness of stem cell treatmentVSAvoidtime required for culture and preparation
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent performs preliminary preparation of stem cells by cryopreserving them in controlled conditions before clinical use. This allows stem cells to be pre-prepared, stored, and readily deployed when needed, eliminating the need for time-consuming culture maintenance and rapid expansion protocols while preserving cell viability and therapeutic effectiveness.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The invention utilizes phase transition technology through cryopreservation, transitioning stem cells from liquid culture state to frozen storage state and back again. This phase change enables long-term preservation of stem cell potency without requiring continuous culture conditions, dramatically reducing preparation time and infrastructure requirements while maintaining treatment reliability.

Inventive Principle:
Principle #36Phase transitions

3Reliability

If skin grafts are used to treat wounds, then the wound coverage is achieved, but the healing time extends to weeks or months and infection risk increases

Engineering Contradiction:
Improvewound coverage effectivenessVSAvoidhealing time
Core Design Contradiction:
ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent extracts and applies only the essential therapeutic components (stem cells and growth factors) needed for wound healing, eliminating the need for full-thickness skin grafts. This targeted approach delivers regenerative cells directly to the wound bed, achieving effective coverage and healing without the extended recovery period and infection risks associated with traditional grafting procedures.

Inventive Principle:
Principle #2Taking out (Extraction)

4Reliability

If high temperature (52°C) is used for treatment, then certain cellular responses are achieved, but protein and DNA degradation risk increases

Engineering Contradiction:
Improvecellular response effectivenessVSAvoidprotein and DNA degradation
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent precisely controls temperature parameters during stem cell application, maintaining temperatures within the safe range of 37-41°C. This optimized temperature control achieves necessary cellular activation and therapeutic response while avoiding the protein denaturation and DNA damage that occur at higher temperatures, ensuring treatment safety and effectiveness.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The applicator enhances the uniform application of treatments, reduces the risk of infection, and accelerates wound healing by providing a stable and effective delivery of stem cells and disinfectants directly to the wound site.

Implementation Method 1

the distal nozzle tip configured to radially deliver electrically spun droplets of the treatment solution from the applicator to the treatment site

Methodology Applied
Scientific EffectElectrospinning: Electrohydrodynamics

Data Source

PatentUS12296128B2Device, systems, and methods of applying a treatment solution to a treatment site
Publication Date: 2025.05.13 OCTET MEDICAL INC
  • US12296128B2 patent drawing
  • US12296128B2 patent drawing
  • US12296128B2 patent drawing

AI summary

Systems and methods of electrostatically spraying a treatment solution are disclosed that include electrostatically charging, by a cartridge assembled with a handheld portable electrostatic device, a treatment solution. The handheld portable electrostatic device can include a housing, the cartridge removably disposed in the housing. The cartridge can include a cartridge housing, at least one electrode to electrostatically charge and ionize molecules of the treatment solution of the cartridge, and a nozzle positioned at a distal end of the cartridge housing, the nozzle of the cartridge being configured to deliver the electrostatically charged treatment solution and configured to be in fluid communication with an air supply tube in fluid communication with a pump in the housing.